Company Description
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease.
Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.
The company was founded in 2000 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Michael McFadden |
Contact Details
Address: 750 West Pender Street, Suite 1200 Vancouver, BC V6C 2T8 Canada | |
| Phone | 604-564-9244 |
| Website | alphacognition.com |
Stock Details
| Ticker Symbol | ACOG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655923 |
| ISIN Number | CA02074J5017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael E. McFadden B.B.A. | Chief Executive Officer and Director |
| Lauren D'Angelo M.B.A. | Chief Operating Officer |
| Kenneth Anthony Cawkell B.A., LL.B. | Founder, Consultant, Corporate Secretary and Director |
| Henry Du CPA | Vice President of Finance and Accounting and Interim Chief Financial Officer |
| Dr. Denis G. Kay Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | SCHEDULE 13G | Filing |
| Apr 10, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |